Library
Growth hormone axisLimited humanRx / compounded

Sermorelin

GRF 1-29 · Geref

The original GHRH analogue — once FDA-approved for pediatric GH deficiency, now used off-label for GH support.

Class

Growth-hormone-releasing hormone (GHRH 1-29) analogue

Half-life

~10–20 minutes

Evidence

Limited human data

Limited human data

Small open-label studies, case series, or trials in a narrow population. Directionally informative, not conclusive.

Overview

Sermorelin is the first 29 amino acids of GHRH — the smallest fragment that retains full activity. It was FDA-approved (as Geref) for diagnosing and treating growth hormone deficiency in children before being withdrawn from the US market for commercial rather than safety reasons. It remains widely available through compounding pharmacies.

Compared with the modified GRF analogues, sermorelin has a shorter half-life and is slightly less potent, but it has the longest human track record of the GHRH family and a well-characterised safety profile from its pediatric use.

In anti-aging and wellness clinics it is prescribed off-label to raise GH and IGF-1 in adults with age-related decline. The controlled evidence for adult body-composition benefit is limited, but its regulatory history and prescriber availability make it one of the more accessible options.

How it works

  • Binds pituitary GHRH receptors to stimulate endogenous GH synthesis and release.
  • Preserves pulsatile GH secretion and hypothalamic-pituitary feedback.
  • Shorter half-life than modified GRF (1-29); slightly lower per-dose potency.
  • Combinable with a ghrelin-mimetic secretagogue for additive effect.

What the research shows

Researched effects

  • Raised GH and IGF-1 in children with GH deficiency (approved use)
  • Increased GH/IGF-1 in adults in smaller studies
  • Anecdotal improvement in sleep, recovery, and body composition
  • Long human safety record from pediatric use

Limitations & what it won't do

  • Limited controlled data for adult anti-aging or body-composition claims.
  • Shorter half-life means it is often dosed at bedtime to catch the overnight pulse.
  • No longer FDA-marketed; quality depends on the compounding pharmacy.

Dosing protocols

These ranges reflect published trials and community protocols. They are reference information, not a prescription. Doses are per injection unless noted.

Adult GH support (compounded)

200–500 mcg
FrequencyOnce daily
RouteSubcutaneous injection
TimingBedtime on an empty stomach, to align with the overnight GH pulse
Cycle3–6 months, reassess

Frequently co-prescribed with ipamorelin. Dose per a licensed prescriber's guidance.

Reconstitution & measuring your dose

Handling

Typical vial sizes
3 · 5 · 9 mg
Suggested BAC water
2 mL
Storage
Lyophilised powder refrigerated at 2–8 °C, protected from light.
After reconstitution
Reconstituted: approximately 30 days refrigerated.

Why 2 mL? A 5 mg vial in 2 mL yields 2500 mcg/mL — 250 mcg lands on 10 units of a U-100 syringe.

Dose calculator

Draw to

8units

= 0.08 mL · 25 mcg per unit

0u100u

Concentration

2500 mcg/mL

Doses per vial

25

Side effects

Common

  • Injection-site redness or pain
  • Flushing
  • Headache
  • Transient dizziness

Serious / rare

  • Reduced insulin sensitivity with prolonged use
  • Hypersensitivity reactions
  • Theoretical tumour stimulation via IGF-1

Contraindications & interactions

Do not use if you have

  • Active cancer or current oncology treatment

    Raises IGF-1; contraindicated during active malignancy.

  • Pregnant, breastfeeding, or trying to conceive

    No pregnancy safety data.

Use caution if you have

  • Type 2 diabetes or insulin resistance

    Monitor glucose — GH pulses reduce insulin sensitivity.

  • Past cancer diagnosis (in remission)

    IGF-1 elevation warrants oncology clearance.

  • Other thyroid disorder

    Untreated hypothyroidism blunts the GH response; correct thyroid status first.

Medication interactions

  • monitorInsulinGlucose may run higher.
  • monitorCorticosteroidsSteroids suppress the GH response.
  • monitorThyroid hormoneThyroid status affects GH secretion; keep it optimised.

What to monitor

  • IGF-1 and GH levels
  • Fasting glucose
  • Thyroid function

Commonly combined with

References

Research & educational information only — not medical advice.

You must be 18 or older to use this site. The peptides described are presented as research chemicals intended for research purposes only. Most are not approved by the FDA for human use. Dosing ranges reflect what has appeared in the scientific literature or community protocols and are not prescriptions. Nothing here replaces evaluation by a licensed physician who knows your full medical history.

Want to know if Sermorelin fits your goals and history?

The assessment cross-checks your medical history and medications against this and every other compound before it recommends anything.

Start the assessment